Entering text into the input field will update the search result below

More on Sangamo Q2 results

Jul. 23, 2014 5:19 PM ETSangamo Therapeutics, Inc. (SGMO) StockBy: Douglas W. House, SA News Editor1 Comment
  • Sangamo BioSciences (NASDAQ:SGMO +6.1%) Q2 results: Total Revenues: $10.4M (+49.8%), Collaboration Agreements: $9.7M (+57.9%); Operating Expenses: $17.4M (+40.6%); Net Loss: ($7.0M) (-28.1%); Quick Assets: $236.7M (+79.6%).
  • 2014 Guidance: Revenues: $45M - 50M; Operating expenses: $65M - 70M; Quick Assets: at least $225M by year end.

Recommended For You

About SGMO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SGMO--
Sangamo Therapeutics, Inc.